Intravenous Senescent Erythrocyte Vaccination Modulates Adaptive Immunity and Splenic Complement Production

• Published in: ACS nano Vol. 18; no. 1; pp. 470 - 482
• Main Authors: He, Yan, Cheng, Chuanxu, Liu, Yuheng, Chen, Fang-Man, Chen, Yinglu, Yang, Chao, Zhao, Zhibin, Dawulieti, Jianati, Shen, Zikun, Zhang, Yunjiao, Du, Jin-Zhi, Guan, Shan, Shao, Dan
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 09.01.2024
• Subjects: complement production; biomimetic vaccine; senescent erythrocyte; splenic targeting; immunotherapy
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.3c07943

Targeted delivery of vaccines to the spleen remains a challenge. Inspired by the erythrophagocytotic process in the spleen, we herein report that intravenous administration of senescent erythrocyte-based vaccines profoundly alters their tropism toward splenic antigen-presenting cells (APCs) for imprinting adaptive immune responses. Compared with subcutaneous inoculation, intravenous vaccination significantly upregulated splenic complement expression in vivo and demonstrated synergistic antibody killing in vitro. Consequently, intravenous senescent erythrocyte vaccination produces potent SARS-CoV-2 antibody-neutralizing effects, with potential protective immune responses. Moreover, the proposed senescent erythrocyte can deliver antigens from resected tumors and adjuvants to splenic APCs, thereby inducing a personalized immune reaction against tumor recurrence after surgery. Hence, our findings suggest that senescent erythrocyte-based vaccines can specifically target splenic APCs and evoke adaptive immunity and complement production, broadening the tools for modulating immunity, helping to understand adaptive response mechanisms to senescent erythrocytes better, and developing improved vaccines against cancer and infectious diseases.